<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171340</url>
  </required_header>
  <id_info>
    <org_study_id>CFEM345D2405</org_study_id>
    <nct_id>NCT00171340</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.</brief_title>
  <official_title>An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment
      of breast cancer and will be randomized to a treatment group to receive either upfront
      zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4
      mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when
      either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar
      spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture
      discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 2, 3, 4 and 5 Years of Therapy.</measure>
    <time_frame>Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.</time_frame>
    <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Bone Mineral Density (BMD)of the Lumbar Spine (L1-L4) Over 5 Years of Therapy.</measure>
    <time_frame>Baseline, 5 years.</time_frame>
    <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Bone Mineral Density (BMD) of the Total Hip at 12 Months, 2 Years, 3 Years, 4 Years and 5 Years After Therapy.</measure>
    <time_frame>Baseline, 12 months. Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.</time_frame>
    <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline</measure>
    <time_frame>Baseline,3 years</time_frame>
    <description>At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1065</enrollment>
  <condition>Bone Loss</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Upfront Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score &lt;= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.</description>
    <arm_group_label>Upfront Zoledronic Acid</arm_group_label>
    <arm_group_label>Delayed Zoledronic Acid</arm_group_label>
    <other_name>ZOL446</other_name>
    <other_name>Zometa®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole tablets 2.5 mg/day taken orally for 5 years.</description>
    <arm_group_label>Upfront Zoledronic Acid</arm_group_label>
    <arm_group_label>Delayed Zoledronic Acid</arm_group_label>
    <other_name>Femara®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage I-IIIa breast cancer

          -  Postmenopausal or recently postmenopausal

          -  Recent surgery for breast cancer

          -  Estrogen Receptor positive and/or progesterone receptor positive hormone receptor
             status

          -  No prior treatment with letrozole

        Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Metastatic disease

          -  Invasive bilateral disease

          -  Clinical or radiological evidence of existing fracture in spine or hip

          -  Prior treatment with IV bisphosphonates in the past 12 months

          -  Current treatment with oral bisphosphonates ( must be discontinued within 3 weeks of
             baseline evaluation)

          -  Use of Tibolone within 6 months

          -  Prior use of parathyroid hormone for more than 1 week

          -  Previous or concomitant malignancy

          -  Abnormal renal function

          -  History of disease effecting bone metabolism

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New South Wales</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Australia</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nemocnice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ebersberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halberstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hoyerswerda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neunkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stadthagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stendal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orbassano Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>110</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>137</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>138</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>139</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hoogeveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jesus Maria</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Victoria</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Surquillo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gea</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ibanez</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Maso</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villaroel</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Locarno</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chang Hwa</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>105</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ratchathew</name>
      <address>
        <city>Khonkaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Castle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>March 22, 2011</results_first_submitted>
  <results_first_submitted_qc>April 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2011</results_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Loss</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>letrozole</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid 4 mg Upfront</title>
          <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Zoledronic Acid 4 mg Delayed</title>
          <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score &lt;= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="532"/>
                <participants group_id="P2" count="533"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="408"/>
                <participants group_id="P2" count="398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Results</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Test Procedure Results</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Required Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid 4 mg Upfront</title>
          <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Zoledronic Acid 4 mg Delayed</title>
          <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score &lt;= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="532"/>
            <count group_id="B2" value="533"/>
            <count group_id="B3" value="1065"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="(36-87)" lower_limit="36" upper_limit="87"/>
                    <measurement group_id="B2" value="58" spread="(37-81)" lower_limit="37" upper_limit="81"/>
                    <measurement group_id="B3" value="57" lower_limit="36" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="532"/>
                    <measurement group_id="B2" value="533"/>
                    <measurement group_id="B3" value="1065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.</title>
        <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid 4 mg Upfront</title>
            <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid 4 mg Delayed</title>
            <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score &lt;= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.</title>
          <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).</description>
          <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication.</population>
          <units>Percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.208" spread="3.4194"/>
                    <measurement group_id="O2" value="-3.617" spread="4.2151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 2, 3, 4 and 5 Years of Therapy.</title>
        <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)</description>
        <time_frame>Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.</time_frame>
        <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication. n in each of the categories is the number of participants who had safety data at baseline and the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Zolendronic Acid 4 mg Upfront</title>
          </group>
          <group group_id="O2">
            <title>Zolendronic Acid 4 mg Delayed</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 2, 3, 4 and 5 Years of Therapy.</title>
          <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)</description>
          <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication. n in each of the categories is the number of participants who had safety data at baseline and the given time point.</population>
          <units>Percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 2 years (n=339,343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.463" spread="4.2691"/>
                    <measurement group_id="O2" value="-4.601" spread="5.5273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 years (n=313,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.730" spread="4.884"/>
                    <measurement group_id="O2" value="-4.871" spread="6.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 years (n=290,294)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.782" spread="5.7300"/>
                    <measurement group_id="O2" value="-5.154" spread="7.1079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 5 years (n=264,264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.308" spread="6.0242"/>
                    <measurement group_id="O2" value="-5.414" spread="7.6185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Bone Mineral Density (BMD)of the Lumbar Spine (L1-L4) Over 5 Years of Therapy.</title>
        <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA)</description>
        <time_frame>Baseline, 5 years.</time_frame>
        <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication. n in each of the categories is the number of participants who had safety data at baseline and the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Zolendronic Acid 4 mg Upfront</title>
          </group>
          <group group_id="O2">
            <title>Zolendronic Acid 4 mg Delayed</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Bone Mineral Density (BMD)of the Lumbar Spine (L1-L4) Over 5 Years of Therapy.</title>
          <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA)</description>
          <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication. n in each of the categories is the number of participants who had safety data at baseline and the given time point.</population>
          <units>Percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 12 months (n=360,369)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.128" spread="3.2106"/>
                    <measurement group_id="O2" value="-3603" spread="4.1808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 years (n=339,343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.300" spread="4.0700"/>
                    <measurement group_id="O2" value="-4.521" spread="5.2624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 years (n=313,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.521" spread="4.5936"/>
                    <measurement group_id="O2" value="-4.869" spread="6.0310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 years (n=290,294)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.529" spread="5.5410"/>
                    <measurement group_id="O2" value="-5.148" spread="6.8803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 5 years (n=264,264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.898" spread="5.7995"/>
                    <measurement group_id="O2" value="-5.427" spread="7.4818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Bone Mineral Density (BMD) of the Total Hip at 12 Months, 2 Years, 3 Years, 4 Years and 5 Years After Therapy.</title>
        <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)</description>
        <time_frame>Baseline, 12 months. Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.</time_frame>
        <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication. n in each of the categories is the number of participants who had safety data at baseline and the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Zolendronic Acid 4 mg Upfront</title>
          </group>
          <group group_id="O2">
            <title>Zolendronic Acid 4 mg Delayed</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Bone Mineral Density (BMD) of the Total Hip at 12 Months, 2 Years, 3 Years, 4 Years and 5 Years After Therapy.</title>
          <description>Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)</description>
          <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication. n in each of the categories is the number of participants who had safety data at baseline and the given time point.</population>
          <units>Percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 12 months (n=419,434)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.222" spread="2.3257"/>
                    <measurement group_id="O2" value="-2.239" spread="3.3614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 years (n=394,393)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.649" spread="2.7333"/>
                    <measurement group_id="O2" value="-2.990" spread="4.4318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 years (n=376,365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.754" spread="3.1375"/>
                    <measurement group_id="O2" value="-3.302" spread="4.8942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 years (n=336,349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.716" spread="3.5228"/>
                    <measurement group_id="O2" value="-3.922" spread="5.6505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 5 years (n=306,314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.615" spread="3.7490"/>
                    <measurement group_id="O2" value="-4.162" spread="6.0270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline</title>
        <description>At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan.</description>
        <time_frame>Baseline,3 years</time_frame>
        <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid 4 mg Upfront</title>
            <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid 4 mg Delayed</title>
            <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score &lt;= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline</title>
          <description>At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan.</description>
          <population>The Safety Population consists of all Randomized Patients who received at least 1 dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Population = Randomized participants who had received at least one dose of randomized treatment medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid 4mg Upfront</title>
          <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1 and Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Zolendronic Acid 4mg Delayed</title>
          <description>Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score &lt;= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cytotoxic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Iris cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Small intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Splenic artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Actinomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Biliary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Breast infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hepatic infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Incision site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Mastitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bone density decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Bunion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Ligament disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Benign gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Salivary gland adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Meningorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Alcoholic psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Breast fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Perineal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Uterine enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Increased viscosity of bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pulmonary vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Skin fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="477" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="486" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862- 778 8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

